Shom Goel1; Joyce O’Shaughnessy2; Antoinette R. Tan3; Boris Krastev4; Hope Rugo5; Philippe Aftimos6; Denise A. Yardley7; Zoran Andric8; Curt Wolfgang9; Jessica A. Sorrentino9; Wenli Tao9; Andrew Beelen9; Rajesh Malik9; and Sarika Jain9
This presentation is the intellectual property of the author/presenter. Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors. Contact them at firstname.lastname@example.org or email@example.com for permission to reprint and/or distribute.
1 Peter MacCallum Cancer Centre, Melbourne, Australia; 2 Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; 3 Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; 4 MHAT Hospital for Women Health Nadezhda, Sofia, Bulgaria; 5 University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA; 6 Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 7 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; 8 Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia; 9 G1 Therapeutics, Research Triangle Park, NC, USA
American Society of Clinical Oncology Annual Meeting | June 4–8, 2021 | Chicago, IL, USA
PRESERVE 2 STUDY
OPTIONAL BIOPSY COLLECTION
Study sponsored by G1 Therapeutics. Medical writing assistance was provided by Farhana Burnett, PhD, from Alligent Europe (Envision Pharma Group), funded by G1 Therapeutics.